Interplay between surgery and pharmacotherapy in multimodality treatment of NSCLC
25 Apr 2025
byDr Alan Sihoe, Consultant in Cardio-Thoracic Surgery, CUHK Medical Centre, Hong Kong
At the 28th Congress of the Asian Pacific Society of Respirology, Dr Alan Sihoe, Consultant in Cardio-Thoracic Surgery, CUHK Medical Centre, Hong Kong, discussed the interplay between pharmacotherapy and surgery in treatment of non-small-cell lung cancer (NSCLC), and emphasized the importance of immunotherapy (IO) timing for maximizing curative surgery rates. Dr Sihoe also shared a case of a patient with stage IVA NSCLC who received surgery in 2017 followed by two lines of tyrosine kinase inhibitor (TKI) treatment and remained well as of November 2024.